HUMA240719P5000
- 0.03
- -0.02-40.00%
Humacyte Newsroom
What's Going On With Huamacyte Shares Tuesday?
Humacyte, Inc. (NASDAQ:HUMA) stock is trending on Tuesday. In July, the company has so far added Dr. John P. Bamforth and Dr. Keith Anthony to its Board of Directors, entered a license agreement
Press Release: Humacyte Board of Directors Strengthened With Addition of John P. Bamforth and Keith Anthony Jones
Humacyte Board of Directors Strengthened with Addition of John P. Bamforth and Keith Anthony Jones DURHAM, N.C., July 16, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage
Humacyte Is Maintained at Buy by BTIG
Humacyte Is Maintained at Buy by
Humacyte Price Target Raised to $11.00/Share From $8.00 by BTIG
Humacyte Price Target Raised to $11.00/Share From $8.00 by
MicroStrategy, Coinbase, Robinhood, Tesla And Other Big Stocks Moving Higher On Monday
U.S. stocks were higher, with the Dow Jones index gaining around 250 points on Monday.Shares of MicroStrategy Incorporated (NASDAQ:MSTR) rose sharply during Monday's session amid a rise Bitcoin.
(HUMA) - Analyzing Humacyte's Short Interest
Humacyte's (NYSE:HUMA) short percent of float has risen 58.68% since its last report. The company recently reported that it has 8.25 million shares sold short, which is 9.14% of all regular shares
BTIG Maintains Humacyte(HUMA.US) With Buy Rating, Raises Target Price to $11
BTIG analyst Ryan Zimmerman maintains $Humacyte(HUMA.US)$ with a buy rating, and adjusts the target price from $8 to $11.According to TipRanks data, the analyst has a success rate of 46.6% and a
Express News | Humacyte Shares Are Trading Higher After the Pluristyx Announced a License Agreement With the Company
Express News | Humacyte Inc : Btig Raises Target Price to $11 From $8
Express News | Pluristyx Announces License Agreement With Humacyte; Humacyte to Use Pluristyx's Clinical-Grade PluriBank IPSC Line for Manufacturing Insulin-Producing Cells for BioVascular Pancreas Product
Express News | Pluristyx Announces License Agreement With Humacyte to Develop Biovascular Pancreas Using Ipscs
Humacyte Price Target Maintained With a $7.00/Share by Cantor Fitzgerald
Humacyte Price Target Maintained With a $7.00/Share by Cantor Fitzgerald
Cantor Fitzgerald Maintains Humacyte(HUMA.US) With Buy Rating, Raises Target Price to $7
Cantor Fitzgerald analyst Kristen Kluska maintains $Humacyte(HUMA.US)$ with a buy rating, and adjusts the target price from $6 to $7.According to TipRanks data, the analyst has a success rate of 37.0%
Humacyte Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/02/2024 160.87% Benchmark $15 → $15 Reiterates Buy → Buy 05/24/2024 160.87% Benchmark $15 → $15 Reitera
Benchmark Co. Maintains Humacyte(HUMA.US) With Buy Rating, Maintains Target Price $15
Benchmark Co. analyst Bruce Jackson maintains $Humacyte(HUMA.US)$ with a buy rating, and maintains the target price at $15.According to TipRanks data, the analyst has a success rate of 28.9% and a tot
While Institutions Own 20% of Humacyte, Inc. (NASDAQ:HUMA), Individual Investors Are Its Largest Shareholders With 50% Ownership
Express News | Humacyte Shares Are Continuing Higher After the Company on Monday Announced It Was Granted Regenerative Medicine Advanced Therapy Designation by the FDA for Patients With Advanced Peripheral Artery Disease
Humacyte (HUMA) Gets a Buy From Benchmark Co.
Why Humacyte Stock Is Trading 15% Higher Monday
Humacyte, Inc. (NASDAQ:HUMA) is moving higher on Monday after receiving the Food and Drug Administration's Regenerative Medicine Advanced Therapy (RMAT) designation for its Acellular Tissue Engineered
Humacyte Stock Rallies 19% on FDA RMAT Designation